The Power of the Web in Cancer Drug Discovery and Clinical Trial Design: Research without a Laboratory?

被引:0
|
作者
Galustian, Christine [1 ]
Dalgleish, Angus G. [1 ]
机构
[1] St Georges Univ London, Dept Oncol, Div Cellular & Mol Med, Cranmer Terrace, London SW17 0RE, England
来源
CANCER INFORMATICS | 2010年 / 9卷
关键词
cancer; drug discovery; data mining; clinical trials;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The discovery of effective cancer treatments is a key goal for pharmaceutical companies. However, the current costs of bringing a cancer drug to the market in the USA is now estimated at $1 billion per FDA approved drug, with many months of research at the bench and costly clinical trials. A growing number of papers highlight the use of data mining tools to determine associations between drugs, genes or protein targets, and possible mechanism of actions or therapeutic efficacy which could be harnessed to provide information that can refine or direct new clinical cancer studies and lower costs. This report reviews the paper by R.J. Epstein, which illustrates the potential of text mining using Boolean parameters in cancer drug discovery, and other studies which use alternative data mining approaches to aid cancer research.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 50 条
  • [21] Revolutionizing Cancer Research and Drug Discovery: The Role of Artificial Intelligence and Machine Learning
    Paliwal, Ajita
    Alam, Md Aftab
    Sharma, Preeti
    Jain, Smita
    Dhoundiyal, Shivang
    CURRENT CANCER THERAPY REVIEWS, 2024,
  • [22] Challenges in breast cancer clinical trial design in the postgenomic era
    Loi, S
    Buyse, M
    Sotiriou, C
    Cardoso, F
    CURRENT OPINION IN ONCOLOGY, 2004, 16 (06) : 536 - 541
  • [23] Clinical Trial Design for HIV Prevention Research: Determining Standards of Prevention
    Dawson, Liza
    Zwerski, Sheryl
    BIOETHICS, 2015, 29 (05) : 316 - 323
  • [24] An economic approach to clinical trial design and research priority-setting
    Claxton, K
    Posnett, J
    HEALTH ECONOMICS, 1996, 5 (06) : 513 - 524
  • [25] Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer
    Rossi, Antonio
    Pilotto, Sara
    Carbognin, Luisa
    Ferrara, Miriam Grazia
    Belluomini, Lorenzo
    Daniele, Gennaro
    Bria, Emilio
    JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (03): : 207 - 222
  • [26] The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery
    Gittelman, Michelle
    RESEARCH POLICY, 2016, 45 (08) : 82 - 97
  • [27] Comparison of automated clinical and research blood pressure measurements: Implications for clinical practice and trial design
    Tang, Olive
    Juraschek, Stephen P.
    Appel, Lawrence J.
    Cooper, Lisa A.
    Charleston, Jeanne
    Boonyasai, Romsai T.
    Carson, Kathryn A.
    Yeh, Hsin-Chieh
    Miller, Edgar R., III
    JOURNAL OF CLINICAL HYPERTENSION, 2018, 20 (12) : 1676 - 1682
  • [28] Outcomes research in cancer clinical trial cooperative groups: The RTOG model
    Bruner, DW
    Movsas, B
    Konski, A
    Roach, M
    Bondy, M
    Scarintino, C
    Scott, C
    Curran, W
    QUALITY OF LIFE RESEARCH, 2004, 13 (06) : 1025 - 1041
  • [29] EpigenPlot: An interactive web platform for DNA methylation-based biomarker and drug target discovery in colorectal cancer
    Mueller, Dalma
    Gyorffy, Balazs
    BRITISH JOURNAL OF PHARMACOLOGY, 2025, 182 (07) : 1452 - 1465
  • [30] Outcomes Research in Cancer Clinical Trial Cooperative Groups: The RTOG Model
    D.W. Bruner
    B. Movsas
    A. Konski
    M. Roach
    M. Bondy
    C. Scarintino
    C. Scott
    W. Curran
    Quality of Life Research, 2004, 13 : 1025 - 1041